With 19 years of stem cell preparation background, ICT U.S. possesses extensive knowledge of stem cell production and preparation. ICT owns and utilizes a variety of international patents to resolve major challenges in the industry. Amongst the many, our patented cellular transport solution that allows for a 95% survival rate and our patented cellular cryopreservation solution that excludes the use of DMSO.
There is a cooperative effort among several institutions that are researching ICT U.S. ‘s clinical practice. These institutions include, but are not limited to: Cedars-Sinai Medical Center, University of Southern California, Keck School of Medicine, Beijing Institute of Genomics Chinese Academy of Sciences, as well as many other industry experts and well-known institutions.
Multinational Corporation (MNC)
ICT U.S. is one of the few institutions in the field of regenerative medicine in the United States with a multi-national, dual-center model, providing both timely service responsiveness and biological transportive abilities between the United States and China.
With more than 10,000 treatment cases averaging over 80% success rate, stem cell transplantation therapy has proven to treat rheumatoid arthritis, Parkinson’s disease, senile dementia, cerebral palsy, spinal cord injury, cerebral hemorrhage, cerebral thrombosis, liver cirrhosis, diabetes, female menopause syndrome, among many others.
With the support of over 15 years of clinical application experience, ICT U.S. has started the FDA application process for IND (Investigational New Drug) for more than five different indications, including orphan drug products for the treatment of rare diseases.
What we provide is not simply medical products or services, but regenerative medical solutions which combine different functional modules to form customized solutions. Our solutions are established on the modules of stem cell collecting, processing, manufacturing, storage, application, therapy, and biological products. According to the varying needs of patients, different functional modules can be combined to form personalized and effective solutions.
Stem Cell: Umbilical cord-derived mesenchymal stem cells (allogeneic and autologous), bone marrow mesenchymal stem cells (allogeneic and autologous), fibroblasts, vascular endothelial cells and supporting cells (allogeneic and autologous), adipose-derived stem cells, HRP cells (retinal pigment epithelial cells), cord blood-derived hematopoietic stem cells; Immunocyte: CIK-DC cells (allogeneic and autologous), NK cells (allogeneic and autologous); Cellular Derivatives: derivatives from cell culture medium based on our patented freeze-drying technology.